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Abstract: This study tested extracts from New Zealand seaweed Undaria pinnatifida 
containing fucoxanthin, in parallel with pure fucoxanthin, in nine human cancer cell lines, 
for anticancer activity. Growth inhibition effects of extracts from Undaria pinnatifida were 
found in all types of cancer cell lines in dose- and time- dependent manners. Cytotoxicity 
of fucoxanthin in three human non-cancer cell lines was also tested. Compared with pure 
fucoxanthin, our extracts containing low level of fucoxanthin were found to be more 
effective in inhibiting the growth of lung carcinoma, colon adenocarcinoma and 
neuroblastoma. Our results suggest that fucoxanthin is a functional biomaterial that may be 
used as a chemopreventive phytochemical or in combination chemotherapy. Furthermore, 
we show for the first time that some unknown compounds with potential selective  
anti-cancer effects may exist in extracts of New Zealand Undaria pinnatifida, and  
New Zealand Undaria pinnatifida could be used as a source for either functional 
biomaterial extraction or production of functional food. 
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1. Introduction 
The ocean represents an abundant resource of novel compounds with great potential for pharmaceutical, 
nutritional supplements, cosmetics, agrichemicals and enzymes [1]. The brown algal genus Undaria 
(Phaeophyceae, Order Laminariales, Family Alariaceae) has been an important dietary component 
since at least sixth century in most Asian countries. Undaria pinnatifida (U. pinnatifida) was 
accidently introduced into New Zealand (NZ) where it was first discovered in the Wellington Harbor 
in 1987 [2]. It is listed as an “unwanted organism” by Biosecurity NZ. As a result, no one could collect 
it and little research has been done on it for more than two decades, and the seaweed spread throughout 
the east coast of NZ primarily on ropes associated with mussel farms. In May 2010, recognizing that 
there is no chance to eradicate this seaweed, the Biosecurity NZ allowed for permits to be issued for 
the collection of U. pinnatifida from artificial structures (e.g., mussel farms) and for it to be farmed in 
areas where it is already prolific. Undaria pinnatifida is a source of biologically active phytochemicals, 
including a wide range of components such as carotenoids, phycobilins, fatty acids, polysaccharides, 
vitamins, sterols, tocopherol, and phycocyanins [3]. The major components in U. pinnatifida such as 
fucoxanthin and fucoidan have been reported to induce apoptosis in various tumor cells [4–8]. 
Fucoxanthin is an abundant marine xanthophyll, and it is the most important pigment in generating 
the brown color in brown seaweeds [9]. The structure of fucoxanthin (Figure 1) contains an unusual 
allelic bond and some oxygenic functional groups such as epoxy, hydroxyl, carbonyl and carbonyl 
moieties. It is a type of carotenoid and possesses anti-oxidative and cancer cell growth inhibition 
effects. Free radicals and oxidative stress are involved in the pathogenesis of cancer disease [9]. 
In vitro studies have demonstrated that fucoxanthin induces apoptosis and enhances growth inhibition 
effects on several cancer cell lines including human promyelocytic leukemia HL-60 cell line [10], 
human colon carcinoma including Caco-2, WiDr, HT-29 and DLD-1 [5], human lung bronchopulmonary 
and epithelial cancer cells NSCLC-N6 and A549 [11], human prostate cancer cell lines such as PC-3, 
DU 145, and LNCaP [12], human hepatocellular cancer cell Hep G2 [13], human gastric adenocarcinoma 
MGC-803 [14], and human neuroblastoma GOTO cells [15]. 
Figure 1. The structure of fucoxanthin. 
 
In order to take full advantage of the benefit of U. pinnatifida growing in NZ, it is important and 
necessary to fully understand its possible chemical composition and potential use, because even the 
same species growing in different environment may produce different functional biomaterial 
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composition, as well as bioactivity. In this study, we investigated the cancer cell growth inhibition of 
extracts, mainly containing fucoxanthin, from U. pinnatifida grown in Marlborough Sounds, South 
Island of NZ. 
2. Results and Discussion 
2.1. HPLC Quantification of Fucoxanthin in U. pinnatifida Extracts  
Fucoxanthin was extracted from the blade (the main part of the plant) and sporophyll (the 
reproductive structure that sits at the bottom of the blade near the plant’s attachment to the substrate) 
of U. pinnatifida, and the HPLC chromatograms of the first and second fucoxanthin extracts are shown 
in Figure 2. Previous data from literature showed that trans-fucoxanthin was the major isomer (~88%) 
found in fresh brown seaweeds, and a small amount was 13-cis and 13’-cis isomers (~9%) [16]. In this 
study, fucoxanthin was detected at 450 nm wavelength. Trans-fucoxanthin peak appeared at the 
retention time of around 1.8 min. The two peaks ascribed as the 13-cis and 13’-cis isomers of 
fucoxanthin were detected at retention times of 2.2 min and 2.4 min, respectively. The peak detected at 
4.3 min was the internal standard canthaxanthin. An unidentified peak was detected at a retention time 
of 3.0 min in both blade and sporophyll. This peak was not purified and investigated further in this 
study. Based on HPLC quantification, the crude, first and second extract contained 0.2%, 43.5% and 
60.8% fucoxanthin, respectively. The ratio of Peak C’s area under the curve against that of the internal 
standard (AUCpeakC/AUCIS) increased with decreased fucoxanthin content in extracts. The crude 
contained the highest AUCpeakC/AUCIS and the 2nd extract contained the lowest AUCpeakC/AUCIS. 
Figure 2. HPLC chromatograms of (a) the 1st NZ U. pinnatifida extract; (b) the 2nd NZ 
U. pinnatifida extract. Peaks in chromatograms: (A) trans-fucoxanthin; (B) cis-fucoxanthin; 
(C) unidentified peak; (D) canthaxanthin (internal standard). 
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2.2. Pure Fucoxanthin on Cancer Cell Growth 
All nine cancer cell lines were treated with pure fucoxanthin (Sigma) at concentrations of 1.5625, 
6.25, 12.5, 25, 50, 80, 100 µM for 24, 48 and 72 h, respectively (Figure 3). There was significant 
difference between high and low concentrations and between 24, 48 and 72 h treatments (p < 0.05). 
This suggests fucoxanthin’s cancer cell growth inhibition effect is time- and dose-dependent.  
Figure 3. Inhibitory effects of pure fucoxanthin standard. All nine cancer cell lines were 
treated with 1.5625, 6.25, 12.5, 25, 50, 80, 100 μM fucoxanthin. Inhibitory effects were 
determined after treatment at 24 h (○), 48 h (□) and 72 h (Δ). Data are expressed as  
mean ± standard errors (n = 6). (a) In Hep G2 cell line; (b) in A549 cell line; (c) in WiDr 
cell line; (d) in NCI-H522 cell line; (e) in SK-N-SH cell line; (f) in Lovo cell line; (g) in 
MCF-7 cell line; (h) in SiHa cell line; (i) in Malme-3M cell line. 
 
For 24-h incubation, SK-N-SH (Figure 3e), SiHa (Figure 3h), and Malme-3M cell lines (Figure 3i) 
showed higher sensitivity to fucoxanthin treatment. For human malignant melanoma cell line  
Malme-3M, cell viability could be significantly decreased starting from 50 µM treatment within 24 h. 
This provides the foundation for further investigation on whether fucoxanthin can be used topically for 
the treatment of melanoma or in combination therapy to assist other melanoma treatments.  
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In 48-h incubations, cell viability in most cancer cell lines decreased in the presence of low fucoxanthin 
concentration. After treatment with pure fucoxanthin standard at 100 µM for 72 h, cell viability in all 
tested cancer cell lines decreased to approximately 20% compared with untreated cell cultures. 
The IC50 values for growth inhibition effects of pure fucoxanthin standard on all cancer cell lines 
are shown in Table 1. The first and the most obvious feature was that the lowest IC50 values were 
found in human malignant melanoma Malme-3M and human cervix squamous carcinoma SiHa cells. 
IC50 values for Lovo, MCF-7, NCI-H522, and A549 cell lines were higher than those of Malme-3M 
and SiHa, but lower than other types of cell lines (p < 0.05). Human neuroblastoma SK-N-SH seemed 
to be less sensitive to pure fucoxanthin treatment. 
Table 1. Inhibition effects IC50 comparison from pure fucoxanthin standard treatment in all 
nine types of cancer cell lines for 48 and 72 h. The p-values were comparison of IC50 with 
Malme-3M and SiHa cell lines. Data are expressed as mean ± standard errors (n = 6). 
Cancer Cell Lines 
IC50 after Fucoxanthin 
Treatment for 48 h 
IC50 after Fucoxanthin 
Treatment for 72 h 
p-values 
Hep G2 58.89 ± 1.23 μM 25.9 ± 1.69 μM p < 0.05 
A549 44.7± 2.26 μM 25.57 ± 1.07 μM p < 0.05 
WiDr 42.26 ± 1.25 μM 25.03 ± 1.63 μM p < 0.05 
NCI-H522 46.11 ± 1.07 μM 24.46 ± 1.58 μM p < 0.05 
SK-N-SH 52.69 ± 1.07 μM 31.21 ± 2.62 μM p < 0.01 
Lovo 39.62 ± 0.94 μM 21.83 ± 1.17 μM p < 0.05 
MCF-7 43.96 ± 2.61 μM 22.48 ± 1.26 μM p < 0.05 
SiHa 37.6± 1.49 μM 18.9 ± 2.16 μM – 
Malme-3M 27.96 ± 1.36 μM 17.33 ± 2.65 μM – 
There are several mechanisms of action that have been proposed for fucoxanthin’s cancer cell 
growth inhibition effect. First, it could induce cell apoptosis reducing the proliferation of human breast 
adenocarcinoma MCF-7 [17–19]. Second, it might contribute to morphological change, triggering the 
terminal differentiation of human lung carcinoma A549 in vitro [11]. Third, in human hepatocellular 
carcinoma Hep G2 and colon adenocarcinoma WiDr, it could arrest the G0/G1 phase of the cell cycle 
and direct inhibition of the DNA replication step. Currently, there is no mechanism of action proposed 
for fucoxanthin’s cancer cell growth inhibition effect on melanoma and cervix squamous carcinoma. 
The results from our study suggest that those two cancer cell lines are very sensitive to the growth 
inhibition effect of pure fucoxanthin. Thus, further study of mechanism of fucoxanthin’s action in 
those types of cancer is warranted, especially in melanoma, because fucoxanthin may be topically 
used, therefore avoiding the complicated issues of drug absorption, metabolism and distribution. 
2.3. Analysis of Fucoxanthin Treatment in Human Non-Cancer Cells 
The most sensitivity to growth inhibition effects of fucoxanthin was found in HUVEC cell lines. 
HDFb and HEK293 were more tolerant to the treatment of fucoxanthin (see IC50 summary in Table 2). 
The IC50 appeared to be lower than in most cancer cell lines. However, at concentration lower than 
IC50, fucoxanthin has less effect on the growth of human non-cancer cell lines. For example, in the 
control study, fucoxanthin at 1.56 μM could even promote the growth of human non-cancer cells. For 
J. Funct. Biomater. 2014, 5 34 
 
HEK293, fucoxanthin still had no growth inhibition effect on cells at 6.25 μM during 24- and 48-h 
treatment. The control study suggests that fucoxanthin at low concentration could exert selective 
cancer cell growth inhibition effect on cancer cells but not on normal human cells. 
Table 2. Comparison of inhibitory effects IC50 values in all nine cancer cell lines and three 
non-cancer cell lines between treatment of pure fucoxanthin and three New Zealand  
U. pinnatifida extracts including crude (contains 0.2% fucoxanthin), first (contains 43.5% 
fucoxanthin) and second (contains 60.8% fucoxanthin) extracts. Data show IC50 (μM) 
after 48-h treatment/72-h treatment, and are expressed as mean ± standard error (n = 6).  
Cell lines Pure fucoxanthin Second extract First extract Crude extract 
Cancer cell line 
Hep G2 
(58.89 ± 1.23)/ 
(25.90 ± 1.69) 
(48.03 ± 2.08)/
(30.85 ± 0.46) 
(43.04 ± 1.96)/
(25.37 ± 1.07) 
(39.6 ± 2.00)/ 
(25.50 ± 1.40) 
A549 
(44.70 ± 2.26)/ 
(25.57 ± 1.07) 
(49.03 ± 1.02 )/
(28.89 ± 2.67) 
(48.88 ± 0.91)/
(28.89 ± 2.67) 
(47.68 ± 0.26)/ 
(21.51 ± 0.54) 
NCI-H522 
(46.11 ± 1.07)/ 
(24.46 ± 1.58) 
(50.89 ± 2.27)/
(25.87 ± 2.07) 
(49.61 ± 2.01)/
(26.58 ± 1.53) 
(31.00 a ± 1.41)/
(14.58 a ± 0.96) 
WiDr 
(42.26 ± 1.25)/ 
(25.03 ± 1.63) 
(42.33 ± 1.53)/
(23.75 ± 2.63) 
(47.11 ± 1.07)/
(20.12 ± 2.95) 
(24.06 a ± 0.57)/
(15.83 a ± 0.44) 
Lovo 
(39.62 ± 0.94)/ 
(21.83 ± 1.17) 
(40.40 ± 2.30)/
(17.39 ± 2.00) 
(30.46 ± 0.59)/
(12.67 ± 0.16) 
(14.18 a ± 0.52)/
(8.84 a ± 0.38) 
SK-N-SH 
(52.69 ± 2.07)/ 
(31.21 ± 1.62) 
(32.92 a ± 2.28)/
(25.51 a ± 4.02)
(30.79 a ± 2.32)/
(17.57 a ± 1.49)
(30.42 a ± 2.41)/
(20.01 a ± 2.42) 
MCF-7 
(43.96 ± 2.61)/ 
(22.48 ± 1.26) 
(37.59 ± 2.29)/
(22.93 ± 2.83) 
(37.38 ± 2.27)/
(27.39 ± 1.83 
35.63 ± 1.65)/ 
(25.12 ±3.46 
SiHa 
(37.76 ± 1.49)/ 
(18.9 ± 2.16 
(29.98 ± 1.52)/
(18.84 ± 1.42) 
(32.8 ± 2.53)/ 
(21.34 ± 1.17) 
(30.86 ± 2.73)/ 
(18.9 ± 2.16) 
Malme-3M 
(27.96 ± 1.36)/ 
(17.33 ± 2.65 
(49.76 ± 2.30)/
(35.09 ± 2.03) 
(44.12 ± 1.86)/
29.8 ± 1.36) 
(33.9 ± 2.99)/ 
(25.13 ± 2.72) 
Non-cancer cell line 
HDFB 
(32.23 ± 2.49)/ 
(15.73 ± 2.18) 
46.48 ± 1.99/ 
21.05 ± 1.54) 
(30.45 ± 2.43)/
16.56 ± 2.66) 
(70.25 a,b ± 3.01)/
(48.85 a,b ± 2.65)
HUVEC 
(3.98 ± 1.56)/ 
(3.36 ± 3.20) 
6.66 ± 1.96/ 
4.42 ± 2.41) 
(5.58 ± 2.71)/ 
(3.92 ± 2.22) 
(16.02 a ± 3.08)/
(7.64 ± 1.25) 
HEK293 
(18.7 ± 2.82/ 
(7.66 ± 2.69) 
(33.89 a ± 1.03)/
(13.48 a ± 1.65)
(36.68 a ± 1.05)/
(14.39 a ± 1.32)
(169.8 a,b ± 2.64)/
(54.33 a,b ± 2.47)
a Significantly different from pure fucoxanthin treatment; b IC50 value in non-cancer cell significantly 
different from IC50 value in cancer cell. 
Fucoxanthin is reported to have few adverse effects on normal cells both in vitro and  
in vivo [20,21]. At a single dose, mortality and abnormalities were found after dosing of 1000 and 
2000 mg/kg in mice in vivo [22]. The 50% lethal dose of fucoxanthin was more than 2000 mg/kg body 
weight [10]. At repeated doses, oral administration of fucoxanthin (purity at 95%) at 750 mg/kg was 
applied to rats for 28 days did not show obvious toxicity [23]. Furthermore, histological study 
suggested no abnormality was found in different tissues including liver, kidney, spleen, and gonadal, 
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after repeating dose of 500 and 1000 mg/kg for 30 day in mice [10]. In addition, the genotoxic/mutagenic 
effects were also not found in mouse bone marrow cells [24,25]. Thus, compared to existing cancer 
cytotoxic chemotherapy, fucoxanthin can generate growth inhibition effects to multiple types of cancer 
cell with low toxicity. 
2.4. Growth Inhibition Effects of U. pinnatifida Extracts in Vitro 
All nine cancer cell lines were treated with 1.5625, 6.25, 12.5, 25, 50, 80, 100 μM of three  
U. pinnatifida extracts, including crude extract (containing 0.2% fucoxanthin), the first fucoxanthin 
extract (containing 43.5% fucoxanthin) and the second fucoxanthin extracts (containing 60.8% 
fucoxanthin) for 24, 48 and 72 h. Results are shown in Figure 4. Concentrations were normalized to 
the percentage of purity of fucoxanthin.  
Figure 4. Inhibitory effects of three extracts from NZ U. pinnatifida (containing 0.2 (Δ), 
43.5 (□) and 60.8% (○) fucoxanthin, respectively) on nine cancer cell lines. Data are 
expressed as mean ± standard errors (n = 6). (a) In Hep G2 cell line; (b) in A549 cell line; 
(c) in WiDr cell line; (d) in NCI-H522 cell line; (e) in SK-N-SH cell line; (f) in Lovo cell 
line; (g) in MCF-7 cell line; (h) in SiHa cell line; (i) in Malme-3M cell line. 
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Overall, the growth inhibition effects from all three NZ U. pinnatifida extracts fitted well with the 
Sigmoid model of negative exponential distribution, showing slightly decreased cell viability in the 
low concentration range followed by relatively steep drop of cell viability and then a plateau. Cancer 
cell viability significantly decreased with increased fucoxanthin concentration.  
IC50 values of pure fucoxanthin standard and our three extracts in cancer and non-cancer cell lines 
were compared in Table 2. After treatment with U. pinnatifida extracts for 48 and 72 h, significant 
differences in growth inhibition IC50 values between pure fucoxanthin and U. pinnatifida extracts were 
found in several cancer cell lines including WiDr, NCI-H522, SK-N-SH and Lovo (Table 2) (p < 0.05). 
The IC50 values of the crude NZ U. pinnatifida extract (0.2% fucoxanthin) for 48 h and 72 h were 
significantly lower than corresponding IC50 values of pure fucoxanthin standard. Especially for colon 
adenocarcinoma cell lines Lovo, the IC50 values of crude extract was almost three times lower than the 
IC50 values of pure fucoxanthin. 
In human neuroblastoma cell line SK-N-SH, the IC50 values of the first and second extracts were 
also significantly lower than that of pure fucoxanthin (Table 2). Since the cells were exposed to the 
same concentration of fucoxanthin (normalized by purity in the experiment), this implicates that there 
may be a single unknown compound or a group of unknown compounds present in the NZ 
U. pinnatifida extracts that is effective in inhibiting cancer cell growth or can reduce cancer cell 
viability synergistically with the presence of fucoxanthin. We observed that the unidentified Peak C (in 
Figure 2) concentration decreased with further purification of fucoxanthin (increase in fucoxanthin 
purity of extracts), which also corresponded to the increase of IC50 value. Investigation of un-identified 
Peak C is currently underway. Another most interesting feature found in Table 2 is that IC50 values 
from crude extracts in non-cancer cell lines were significantly higher than the corresponding IC50 
values from pure fucoxanthin treatment. Comparing IC50 values between cancer and non-cancer cell 
lines treated with crude extract, the IC50 values in two non-cancer lines were significantly higher than 
that in all nine cancer cell lines after 48 h and 72 h treatment. Furthermore, with the increase of 
fucoxanthin purity in extracts, the selectivity started to disappear; which indicates that the purification 
process eliminated the compound(s) that may have exerted its effect together with fucoxanthin. These 
findings clearly indicate that fucoxanthin with co-existing compounds in the crude extract can 
selectively inhibit cancer cell growth without exerting high toxicity to non-cancer cells. This provides 
a foundation for future functional food or biomaterial development from NZ U. pinnatifida extracts, 
especially in terms of cancer treatment or prevention.  
Most seaweed composition studies suggest that seaweeds offer a wide range of therapeutic 
possibilities, and report that seaweeds are low in fats but usually contain vitamins and bioactive 
compounds such as terpenoids and polyphenolic compounds [26–28]. In this study, the crude  
U. pinnatifida extracts were achieved by soaking its powder in pure methanol. In the process of 
extraction, pure hexane was used to remove non-polar substance such as carotene and chlorophyll 
compounds. Then silica gel chromatography was used as a purification process using normal phase 
chromatography. As a result, the extracts were removed from those known bioactive compounds. 
Therefore, the reason for the lower IC50 values of U. pinnatifida fucoxanthin extracts compared with 
fucoxanthin in brain tumor, colon, lung cancer cell lines should be the existence of currently  
un-identified (or novel) compound(s). Another compound that has growth inhibition effects in  
U. pinnatifida is fucoidan [4,5,7,8,29]. Fucoidan refers to a type of sulfated polysaccharide. The 
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solubility of polysaccharide compound is reasonably high in water, and it has limited solubility in 
organic solvents such as methanol and ethanol [30,31]. Since we used organic solvent extraction, 
fucoidan was not present in the extracts in significant amount. This further strengthened our conclusion 
that novel cancer cell growth inhibition compound(s) exists in NZ U. pinnatifida. Such compound(s) 
exhibit selective toxicity against cancer cells either by themselves or by co-existing with fucoxanthin. 
3. Experimental Section 
3.1. Materials 
3.1.1. Materials for Fucoxanthin Extraction 
Methanol, hexane, and chloroform were certified as HPLC grade and purchased from Thermofisher 
(Auckland, NZ). Silica gel powder (60–200 MESH) was purchased from J.T. Baker Chemical 
(Auckland, NZ), and benzene was from B.D.H. Ltd (Auckland, NZ). Pure fucoxanthin and internal 
standard canthaxanthin were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
3.1.2. Materials for Cell Viability Assay 
RPMI medium 1640, Cascade Biologic Medium 200, Dulbecco’s Modified Eagle Medium DMEM 
(1×), Low serum growth supplement (LSGS), L-glutamine-200mM (100×) liquid, Penicillin-Streptomycin 
(100 mL), Trypan Blue Stain and TrypLE™ Express Stable Trypsin Replacement Enzyme without phenol 
red were supplied by Invitrogen NZ Ltd (Auckland, NZ). Sterile filtered fetal bovine serum (FBS) was 
purchased from Medica Pacifica (Auckland, NZ). MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl 
tetrazolium bromide] was supplied by Sigma. DMSO (Dimethyl sulfoxide), was purchased by  
Merck-Chemicals (Poole, UK).  
3.1.3. Human Cancer Cell Lines and Cell Culture 
Human cancer cell lines used in this study were purchased from ATCC (Cryosite Ltd., Sydney, 
NSW, Australia), including lung carcinoma line A549, colon adenocarcinoma lines WiDr and Lovo, 
lung cancer line NCI-H522, hepatocellular carcinoma line Hep G2, neuroblastoma line SK-N-SH, 
breast adenocarcinoma line MCF, cervix squamous line SiHa, and malignant melanoma line  
Malme-3M. All nine cell lines were maintained in RPMI 1640 culture medium supplemented with 1% 
Penicillin-Streptomycin, 4 mM L-glutamine and 10% of FBS except Malme-3M (20% FBS). All 
cancer cell lines were maintained in tissue culture incubator at 37 °C and 5% carbon dioxide. 
3.2. Human Non-Cancer Cell Lines and Cell Culture 
Three human non-cancer cell lines including human dermal fibroblasts (HDFb), human umbilical 
vein endothelial (HUVEC) and human embryonic kidney (HEK293) were used to determine in vitro 
toxicity of pure fucoxanthin and extracts from NZ U. pinnatifida. All three cell lines were purchased 
from Invitrogen NZ Ltd. HDFb was maintained in Dulbecco’s Modified Eagle Medium supplemented 
with LSGS. HUVEC cells were maintained in Cascade Biologics Medium 200 supplemented with 
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LSGS. HEK293 cells were maintained in RPMI 1640 culture medium supplemented with 1% 
Penicillin-Streptomycin, 4 mM L-glutamine and 10% of FBS. 
3.3. Preparation of Fucoxanthin 
3.3.1. U. pinnatifida Sample Preparation 
U. pinnatifida was collected from Port Underwood (Marine Farms PE327 and 106) and Pelorus 
Sound of Marlborough Sound (Marine Farms 122 and 353) in NZ, and the samples were collected at 
monthly intervals from June to December 2011. All sample preparation procedures have described in 
one of our previous publications [32]. 
3.3.2. Fucoxanthin Extraction 
U. pinnatifida samples were soaked in pure methanol and stirred mechanically for 48 h in dark 
condition at the room temperature to reduce the possibility of oxidation by sunlight. The ratio for 
extraction between U. pinnatifida sample and pure methanol is 100 g: 1 L. The extract was then 
filtered (Whatman No.1 filter paper, Thermofisher, Auckland, NZ) to remove the solids. This 
procedure was repeated until the seaweed powder was colorless. All methanol extracts were then 
combined. This was the crude U. pinnatifida extract. Hexane and distilled water were added into the 
crude fucoxanthin extract. The lower layer consisted of the methanol/water fraction was collected. The 
chloroform was then added into methanol/water extract. The ratio for pure methanol, pure hexane and 
pure chloroform was 15:15:10 (V/V/V). The mixture was then transferred to centrifuge for 15 min at 
room temperature, 12,000 rpm in a Sorvall RC5C instruments (Dupont, Wilmington, DE, USA) using 
the Fiberlite  F21-8×50y rotor (Thermo-Fisher, San Jose, CA, USA). The organic layer was stored and 
dried at 30 °C using rotary evaporator. Then, the fucoxanthin fraction was freeze dried further to 
completely remove chloroform. 
3.3.3. Silica Gel Column Chromatography Purification 
Due to a higher polarity solvent, pure benzene was used to dissolve the fucoxanthin sample. Pure 
hexane was the solvent in the silica gel column. There were four types of elution including pure 
hexane, about 300 mL of n-hexane/acetone (8:2, V/V) (which remove chlorophyll, carotenoids other 
than fucoxanthin and other impurities), about 400 mL of n-hexane/acetone (6:4, V/V) (which elute 
crude purified fucoxanthin out of the column) and acetone.  
Each fraction was collected and detected by using a UV-visible spectrophotometer (Ultrospec 2100, 
UV-visible Amersham Pharmacia Biotech, Cambridge, UK) at 450 nm. Fractions that had high 
absorbance values at 450 nm were combined. This was the first fucoxanthin extract. Half of the extract 
was dried using a rotary evaporator at 30 °C and freeze-dried in a freeze dryer overnight. The 
remaining half of the first fucoxanthin extract was put back into the silica column repeating the 
procedure above to obtain the second fucoxanthin extract. The second fucoxanthin extract was dried 
using a rotary evaporator and sample was freeze dried in a freeze dryer overnight. Before drying two 
fucoxanthin extracts above, the purified fucoxanthin was quantified using HPLC. Both first and second 
fucoxanthin extract were flushed with argon gas and stored in −80 °C freezer until further use. 
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3.3.4. HPLC Analysis 
Fucoxanthin was determined using a HPLC method [33]. HPLC system consists of a LC-20AT 
pump system (Shimadzu, Tokyo, Japan), a UV-Vis SPD-20A (Shimadzu) absorbance detector and 
online analysis software (LC Solution version 1.25). The separation was achieved by using a  
Luna 5 μM C18 (4.6 mm × 250 mm, Phenomenex, Torrance, CA, USA) reverse phase column. The 
mobile phase was HPLC graded pure methanol at flow rate of 1 mL/min. The volume of sample 
injection was 50 μL. The wavelength for fucoxanthin detection was set at 450 nm. 
Pure fucoxanthin with concentration range of 0.0078–0.125 μg/mL in pure methanol was used to 
construct a standard calibration curve. Canthaxanthin standard (0.0625 μg/mL) was dissolved in pure 
acetone and used as an internal standard. This HPLC method has been validated as described in our 
previous publication [32]. 
3.4. Cell Viability Assay 
Cell viability was determined by MTT assay as previously described [34] with a slight modification. 
Briefly, the optimized seeding cell density was 5000 cells/well for A549 and WiDr, while for Hep G2, 
Malme-3M, SiHa, NCI-H522, Lovo, SK-N-SH, and MCF-7, the seeding cell density was  
10,000 cells/well. Microplate with 96 wells was used for the experiment and each well contained  
100 μL of medium with cancer cells. Treatment time was 24, 48 or 72 h. All cancer cell lines were 
cultured in the presence or absence of fucoxanthin extract or standard.  
Pure fucoxanthin standard and all U. pinnatifida fucoxanthin extracts were dissolved in pure 
ethanol to 5 mM as a stock solution, and the final ethanol concentration was 2% in the culture medium. 
An aliquot of 20 μL of MTT reagent in phosphate buffer saline at a concentration of 5 mg/mL was 
added into each well after experiment, and washed with 150 µL of PBS. After incubation for 4 h at 
37 °C, the formed MTT-formazan was dissolved in 150 μL DMSO. The viable cell amount was 
determined by the absorbance at 540 nm using a multiplate-reader (UV-visible FLUOStar Omega 
Multidetection Microplate Reader, AlphaTech NZ Ltd., Auckland, New Zealand). The IC50 calculated 
represents the effective concentration of extract which gives 50% inhibition of the cell growth and the 
IC50 value was generated by using Prism (GraphPad, La Jolla, San Diego, CA, USA) software. 
3.5. Statistical Analysis 
All results were examined by statistic software Minitab® (Version 16). Two-way ANOVA Turkey’s 
multiple comparison tests was carried out. Compared with control group (the group without standard 
or extract treatment added), the cancer cell growth inhibition effects of treatment was considered to  
be significant if the p value was <0.05. To compare treatments, one way ANOVA with Turkey’s  
test was employed to compare crude U. pinnatifida extract, first fucoxanthin extract and second 
fucoxanthin extract.  
4. Conclusions 
NZ U. pinnatifida contains fucoxanthin, which possesses growth inhibition effects on multiple 
types of cancer cells, in particular melanoma and cervix squamous carcinoma. At a low concentration, 
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fucoxanthin showed selective cytotoxicity to one malignant melanoma line. Therefore, NZ  
U. pinnatifida could be a potential source of fucoxanthin for pharmaceutical use to treat or prevent 
those two types of cancer, or could be used as a type of food for health to reduce the incidence of those 
two types of cancer. It is also possible that fucoxanthin could be used at relative low doses in the 
combination chemotherapy with other cytotoxic anticancer drugs, because at low concentration, it 
exhibits selective cancer cell growth inhibition effect to cancer cells. The limitation of the current 
study is that in vivo conditions are always different from in vitro conditions, and our findings may not 
be able to be translated into in vivo success. A thorough mechanism of action study would have 
provided more clues for potential future applications of fucoxanthin.  
This is the first study to investigate extracts from NZ U. pinnatifida, which has not been 
comprehensively studied before because of its invasive species status in the past. It is highly likely that 
NZ U. pinnatifida extracts contain novel compound(s) with selective cancer cell growth inhibition 
effects in cancer cells, especially in human colon adenocarcinoma, lung carcinoma and neuroblastoma. 
Co-existence of fucoxanthin and the unknown compound(s) in NZ U. pinnatifida extract exhibits 
selective toxicity against cancer cells, but not to non-cancer cells. Additional research is needed to 
identify such compound(s), which would be highly desirable in the field of cancer research. Our 
research has provided the foundation for such further investigation. Nevertheless, even without 
identifying the actually compound(s), it can be concluded that NZ U. pinnatifida is a resource rather 
than a marine pest. It can definitely be used as a source for either functional biomaterial extraction or 
functional food production.  
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